Streptococcus suis is a Gram-positive pathogen that causes serious diseases in pigs. In addition to S. suis serotype 2 (SS2), S. suis serotype 9 (SS9) is another prevalent serotype, which is frequently isolated fr...Streptococcus suis is a Gram-positive pathogen that causes serious diseases in pigs. In addition to S. suis serotype 2 (SS2), S. suis serotype 9 (SS9) is another prevalent serotype, which is frequently isolated from the organs of diseased pigs in China. An immunoproteomic-based approach was developed to identify antigens common to SS2 and SS9 for vaccine development. Cell wall proteins extracted from SS2 strain HA9801 were screened by two-dimensional Western blot using anti-SS2 sera, anti-SS9 sera, or pre-immune sera pooled from specific pathogen free (SPF) mice. Protein spots on preparative gels were excised and identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, which led to the identification of four shared immunogenic proteins (arginine deiminase, translation elongation factor-Ts, o-acetylserine lyase, and 1-phosphofructokinase). The genes encoding these four proteins from SS9 strain GZ0565 were cloned and their proteins were overexpressed in Escherichia coli BL21. Western blot analysis of these recombinant proteins using the convalescent serum of an SPF mini-pig inoculated with the SS2 strain, anti-SS2 sera, and anti-SS9 sera pooled from SPF mice further confirmed the immunogenicity of these proteins. These immunogenic proteins, which are encoded by genes that are reasonably conserved among SS2 and SS9 strains, could be developed as vaccine candidates.展开更多
试验旨在研制具有高抗原活性的猪链球菌2型(Streptococcus suis type 2,SS2)疫苗培养基。研究以SS2 CVCC60615株为试验对象,通过单因素试验、Plackett-Burman试验、最陡爬坡试验和响应面分析得到SS2疫苗培养基。培养基发酵验证结果显示,...试验旨在研制具有高抗原活性的猪链球菌2型(Streptococcus suis type 2,SS2)疫苗培养基。研究以SS2 CVCC60615株为试验对象,通过单因素试验、Plackett-Burman试验、最陡爬坡试验和响应面分析得到SS2疫苗培养基。培养基发酵验证结果显示,SS2疫苗培养基菌液最大活菌数为1.09×10^(9) CFU/mL,是TSB培养基最大活菌数的2.41倍。测定SS2不同时间点的抗原活性发现,在SS2发酵培养过程中当活菌数达到最大值后的1~3 h内细菌的抗原活性最高。小鼠感染试验表明,SS2抗原活性最高时制备的灭活疫苗与商品化灭活疫苗相比具有更高的免疫球蛋白G(IgG)抗体效价和疫苗保护率。研究表明,采用研制得到的高抗原活性SS2疫苗培养基制备的灭活疫苗具有IgG抗体效价高、免疫保护力强的优点。展开更多
基金the fund of the Priority Academic Program Development of Jiangsu Higher Education Institutions, China (PAPD)the Natural Science Foundation of Jiangsu Province, China (BK2011644)+2 种基金the Youth Foundation of National Natural Science Foundation of China (31101828)the Youth Foundation of Nanjing Agricultural University, China (KJ2011012)the Specialized Research Funds for the Doctoral Program of Higher Education of China (20110097120016, 20110097130003)
文摘Streptococcus suis is a Gram-positive pathogen that causes serious diseases in pigs. In addition to S. suis serotype 2 (SS2), S. suis serotype 9 (SS9) is another prevalent serotype, which is frequently isolated from the organs of diseased pigs in China. An immunoproteomic-based approach was developed to identify antigens common to SS2 and SS9 for vaccine development. Cell wall proteins extracted from SS2 strain HA9801 were screened by two-dimensional Western blot using anti-SS2 sera, anti-SS9 sera, or pre-immune sera pooled from specific pathogen free (SPF) mice. Protein spots on preparative gels were excised and identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, which led to the identification of four shared immunogenic proteins (arginine deiminase, translation elongation factor-Ts, o-acetylserine lyase, and 1-phosphofructokinase). The genes encoding these four proteins from SS9 strain GZ0565 were cloned and their proteins were overexpressed in Escherichia coli BL21. Western blot analysis of these recombinant proteins using the convalescent serum of an SPF mini-pig inoculated with the SS2 strain, anti-SS2 sera, and anti-SS9 sera pooled from SPF mice further confirmed the immunogenicity of these proteins. These immunogenic proteins, which are encoded by genes that are reasonably conserved among SS2 and SS9 strains, could be developed as vaccine candidates.
文摘试验旨在研制具有高抗原活性的猪链球菌2型(Streptococcus suis type 2,SS2)疫苗培养基。研究以SS2 CVCC60615株为试验对象,通过单因素试验、Plackett-Burman试验、最陡爬坡试验和响应面分析得到SS2疫苗培养基。培养基发酵验证结果显示,SS2疫苗培养基菌液最大活菌数为1.09×10^(9) CFU/mL,是TSB培养基最大活菌数的2.41倍。测定SS2不同时间点的抗原活性发现,在SS2发酵培养过程中当活菌数达到最大值后的1~3 h内细菌的抗原活性最高。小鼠感染试验表明,SS2抗原活性最高时制备的灭活疫苗与商品化灭活疫苗相比具有更高的免疫球蛋白G(IgG)抗体效价和疫苗保护率。研究表明,采用研制得到的高抗原活性SS2疫苗培养基制备的灭活疫苗具有IgG抗体效价高、免疫保护力强的优点。